Expert Outlook: Ionis Pharmaceuticals Through The Eyes Of 6 Analysts
In the latest quarter, 6 analysts provided ratings for Ionis Pharmaceuticals (NASDAQ:IONS), showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 4 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 3 | 0 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
Analysts have recently evaluated Ionis Pharmaceuticals and provided 12-month price targets. The average target is $98.17, accompanied by a high estimate of $110.00 and a low estimate of $87.00. Marking an increase of 15.05%, the current average surpasses the previous average price target of $85.33.
Diving into Analyst Ratings: An In-Depth Exploration
The analysis of recent analyst actions sheds light on the perception of Ionis Pharmaceuticals by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Allison Bratzel | Piper Sandler | Raises | Overweight | $87.00 | $77.00 |
| Yanan Zhu | Wells Fargo | Raises | Overweight | $100.00 | $82.00 |
| Luca Issi | RBC Capital | Raises | Outperform | $95.00 | $82.00 |
| Mani Foroohar | Leerink Partners | Raises | Outperform | $100.00 | $85.00 |
| Jason Gerberry | B of A Securities | Raises | Buy | $97.00 | $86.00 |
| Mitchell S. Kapoor | HC Wainwright & Co. | Raises | Buy | $110.00 | $100.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Ionis Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ionis Pharmaceuticals compared to the broader market.
- Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Ionis Pharmaceuticals's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Ionis Pharmaceuticals analyst ratings.
Get to Know Ionis Pharmaceuticals Better
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
Ionis Pharmaceuticals: A Financial Overview
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Ionis Pharmaceuticals displayed positive results in 3M. As of 30 September, 2025, the company achieved a solid revenue growth rate of approximately 17.12%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Ionis Pharmaceuticals's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -82.06%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Ionis Pharmaceuticals's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -20.58%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Ionis Pharmaceuticals's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -4.27%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Ionis Pharmaceuticals's debt-to-equity ratio stands notably higher than the industry average, reaching 2.41. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
Analyst Ratings: What Are They?
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.